JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Negative 73.7%

Neg 73.7% Neu 0% Pos 0%

JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $27 to $25.